Targeting cancer complexity at origin and progression
Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).
Group members
Principal investigator
Research assistant
PhD student
PhD student
PhD student
PhD student
Publications
Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4. ABSTRACT A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-23162-4. PMID:33990587 | PMC:PMC8121813 | DOI:10.1038/s41467-021-23162-4
Sci Rep. 2021 May 13;11(1):10171. doi: 10.1038/s41598-021-89562-0. ABSTRACT There are few published data on long-term treatment with sirolimus in lymphangioleiomyomatosis (LAM). The objective of this study was to describe the long-term effect of sirolimus in a series of LAM patients followed up in a referral centre, focusing on pulmonary function. We retrospectively reviewed a series […]
Nat Commun. 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3. ABSTRACT Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but […]
Sci Transl Med. 2021 Feb 10;13(580):eabc4465. doi: 10.1126/scitranslmed.abc4465. ABSTRACT Among the pleotropic roles of transforming growth factor-β (TGFβ) signaling in cancer, its impact on genomic stability is least understood. Inhibition of TGFβ signaling increases use of alternative end joining (alt-EJ), an error-prone DNA repair process that typically functions as a “backup” pathway if double-strand break […]
J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105. ABSTRACT Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes considerably increase breast and ovarian cancer risk. Given that tumors with these mutations have elevated genomic instability, they exhibit relative vulnerability to certain chemotherapies and targeted treatments based on poly (ADP-ribose) polymerase (PARP) inhibition. However, the molecular mechanisms […]
Research Projects
The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.
Collaborations
CIMBA – Consortium of Investigators of Modifiers of BRCA1/2
https://cimba.ccge.medschl.cam.ac.uk/
Lobular Breast Cancer
https://lobsterpot.eu/
BRCA1 breast cancer
Khokha Lab
https://medbio.utoronto.ca/faculty/khokha
Hakem Lab
https://medbio.utoronto.ca/faculty/hakem
Maxwell Lab
https://www.bcchr.ca/cmaxwell
Serra Lab
https://vhio.net/biosketch-violeta-serra/
Cancer biology
Schramek Lab
https://schramek.lunenfeld.ca/
Li Lab
https://lilab.smhs.gwu.edu/
Barcellos-Hoff Lab
https://barcelloshofflab.ucsf.edu/principal-investigator
Cancer genetics
De Cid Lab – GCAT
http://www.gcatbiobank.org/
LAM research
Johnson Lab – LAM UK
https://www.nottingham.ac.uk/medicine/people/simon.johnson
Elżbieta Radzikowska
National Tuberculosis and Lung Diseases Research Institute, Poland
Kwiatkowski Lab
https://www.kwiatkowskilab.org/
AELAM
https://www.aelam.org/
VHIR
https://vhir.vallhebron.com/en/research/pneumology
Molina Lab
https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Menendez’s Lab